[go: up one dir, main page]

WO2016066722A3 - Bacteriophage combinations for human or animal therapy - Google Patents

Bacteriophage combinations for human or animal therapy Download PDF

Info

Publication number
WO2016066722A3
WO2016066722A3 PCT/EP2015/075046 EP2015075046W WO2016066722A3 WO 2016066722 A3 WO2016066722 A3 WO 2016066722A3 EP 2015075046 W EP2015075046 W EP 2015075046W WO 2016066722 A3 WO2016066722 A3 WO 2016066722A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
bacteria
site
encountered
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/075046
Other languages
French (fr)
Other versions
WO2016066722A2 (en
Inventor
Ian Humphery-Smith
Alexander Yurievich ZURABOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2016066722A2 publication Critical patent/WO2016066722A2/en
Publication of WO2016066722A3 publication Critical patent/WO2016066722A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a means of treating and preventing bacterial infection through numerous highly-specific bacteriophage strains that combine to fight a target infection. According to the invention, each composition or combined preparation contains classes of multiple bespoke building blocks/elements (specific bacteriophage strains) directed against: (a) the "target" pathogenic bacterial species in a given host tissue, organ or organ system; (b) bacteria which are likely to co- infect and / or colonise the patient in a site-specific manner, which are capable of producing disease (pathogenic) once that target species has been removed, particularly in a healthcare setting; (c) commonly-encountered bacteria likely to be encountered opportunistically throughout the body (in a non-site-specific manner), particularly in a healthcare setting; and (d) clonally-expanded multi-drug-resistant bacteria particularly of the same target species, as in (a) above, and especially those prevalent in a defined area.
PCT/EP2015/075046 2014-10-28 2015-10-28 Bacteriophage combinations for human or animal therapy Ceased WO2016066722A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014143417 2014-10-28
RURU2014143417 2014-10-28

Publications (2)

Publication Number Publication Date
WO2016066722A2 WO2016066722A2 (en) 2016-05-06
WO2016066722A3 true WO2016066722A3 (en) 2016-06-23

Family

ID=54478005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/075046 Ceased WO2016066722A2 (en) 2014-10-28 2015-10-28 Bacteriophage combinations for human or animal therapy

Country Status (1)

Country Link
WO (1) WO2016066722A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11654166B2 (en) 2018-01-02 2023-05-23 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating Staphylococcus infection
WO2020237044A1 (en) * 2019-05-21 2020-11-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bacteriophages for the treatment of tuberculosis
CN116036006B (en) * 2023-03-08 2023-12-15 领致生物科技(昆山)有限公司 Phage suppository and application thereof in treating bacterial prostatitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080823A2 (en) * 2002-03-25 2003-10-02 University Of Warwick Bacteriophages useful for therapy and prophylaxis of bacterial infections
WO2013141730A1 (en) * 2012-03-19 2013-09-26 Tecnifar-Indústria Técnica Farmacêutica, S.A. Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080823A2 (en) * 2002-03-25 2003-10-02 University Of Warwick Bacteriophages useful for therapy and prophylaxis of bacterial infections
WO2013141730A1 (en) * 2012-03-19 2013-09-26 Tecnifar-Indústria Técnica Farmacêutica, S.A. Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABEDON S T ET AL: "Phage treatment of human infections", BACTERIOPHAGE 2011 LANDES BIOSCIENCE USA, vol. 1, no. 2, March 2011 (2011-03-01), pages 66 - 85, XP002753545, ISSN: 2159-7073 *
BENJAMIN K CHAN ET AL: "Phage cocktails and the future of phage therapy", FUTURE MICROBIOLOGY, vol. 8, no. 6, 1 June 2013 (2013-06-01), GB, pages 769 - 783, XP055245118, ISSN: 1746-0913, DOI: 10.2217/fmb.13.47 *
HANLON ET AL: "Bacteriophages: an appraisal of their role in the treatment of bacterial infections", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 30, no. 2, 27 June 2007 (2007-06-27), pages 118 - 128, XP022132522, ISSN: 0924-8579, DOI: 10.1016/J.IJANTIMICAG.2007.04.006 *
JIKIA D ET AL: "The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90.", CLINICAL AND EXPERIMENTAL DERMATOLOGY JAN 2005, vol. 30, no. 1, January 2005 (2005-01-01), pages 23 - 26, XP002753547, ISSN: 0307-6938 *
KUTATELADZE M ET AL: "Phage therapy experience at the Eliava Institute", MEDECINE ET MALADIES INFECTIEUSES, SOCIETE FRANCAISE D'EDITIONS MEDICALES, PARIS, FR, vol. 38, no. 8, 1 August 2008 (2008-08-01), pages 426 - 430, XP025466625, ISSN: 0399-077X, [retrieved on 20080806], DOI: 10.1016/J.MEDMAL.2008.06.023 *
MARKOISHVILI KALISTRAT ET AL: "A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds.", INTERNATIONAL JOURNAL OF DERMATOLOGY JUL 2002, vol. 41, no. 7, July 2002 (2002-07-01), pages 453 - 458, XP002753546, ISSN: 0011-9059 *
MERABISHVILI MAYA ET AL: "Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 3, 1 March 2009 (2009-03-01), pages e4944 - 1, XP002543299, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0004944 *
SUNAGAR R ET AL: "Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice", RESEARCH IN MICROBIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 161, no. 10, 1 December 2010 (2010-12-01), pages 854 - 860, XP027553043, ISSN: 0923-2508, [retrieved on 20100922] *
TIMOTHY K LU ET AL: "The next generation of bacteriophage therapy", CURRENT OPINION IN MICROBIOLOGY, vol. 14, no. 5, 2011, pages 524 - 531, XP028312588, ISSN: 1369-5274, [retrieved on 20110730], DOI: 10.1016/J.MIB.2011.07.028 *

Also Published As

Publication number Publication date
WO2016066722A2 (en) 2016-05-06

Similar Documents

Publication Publication Date Title
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2025009223A (en) Clec9a binding agents and use thereof
WO2018033254A3 (en) Rna for cancer therapy
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2017030823A3 (en) Anti-tigit antibodies
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2015138716A3 (en) Anti-infective and osteogenic compositions and methods of use
HK1253734A1 (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP4414385A3 (en) Polyomavirus neutralizing antibodies
EP4218823A3 (en) Novel polymeric hgh prodrugs
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX386702B (en) HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY.
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2018115432A3 (en) Compounds for the treatment of bovine or swine respiratory disease
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
MX2021005421A (en) C11-cyclic substituted 13-membered macrolides and uses thereof.
WO2016066722A3 (en) Bacteriophage combinations for human or animal therapy
MY197042A (en) Compounds
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15791263

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15791263

Country of ref document: EP

Kind code of ref document: A2